Session Name: Hepatocellular Carcinoma and Other Malignancies
Session Type: Rapid Fire Oral Abstract
Date: Sunday, June 5, 2022
Session Time: 3:30pm-5:00pm
Presentation Time: 3:40pm-3:50pm
Location: Hynes Room 312
*Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after LT reduce the proportion of adaptive components of cellular immunity while maintaining innate components. Natural killer (NK) cells play a central role in innate immunity against neoplastic cells; therefore, their augmentation is a promising immunotherapeutic approach against HCC recurrence after LT.
*Methods: We propose that adoptive transfer of IL-2-stimulated TRAIL+ NK cells extracted from donor liver graft perfusate can mount an anti-tumor response without causing toxicity to intact recipient tissues.
*Results: In the 98 patients who met the Japan criteria preoperatively, the postoperative pathologically exceeding the Milan criteria (n=41) had a significantly poorer recurrence-free survival rate than those within the Milan criteria (n=57) (p=0.022). However, among the cases outside the Milan criteria, 17 cases treated with NK cell therapy had a significantly better recurrence-free survival rate. After infusion of NK cells, the NK cytotoxicity and the proportion of TRAIL+ NK cells in the peripheral blood of patients increased significantly (p<0.05). The inoculated donor NK cells could be confirmed up to 1 month through the analysis of peripheral blood chimerism. We also applied the proposed approach to the deceased donor LT (DDLT) recipients in collaboration with the US since 2009. This phase I study included 17 subjects with a median follow-up of 96 months. No study-related adverse events were noted in either of the studies. Regarding overall survival, the high-dose group had significantly better survival than the low-dose group (p = 0.0064). In the series of DDLT with HCC, among the 17 patients who met MC on preoperative imaging, 9 patients (53%) had HCC exceeding MC on postoperative pathology. None of the patients have shown any symptom of HCC recurrence. Interestingly, the number of HLA mismatch between donor and recipient was associated with tumor recurrence after NK cell therapy.
*Conclusions: In conclusions, the administration of IL-2-stimulated NK cells derived from both living and deceased donor liver allografts was safely applied and is, therefore, a potential novel adjuvant immune treatment after LT in HCC patients.
To cite this abstract in AMA style:Ohira M, Imaoka Y, Sato K, Imaoka K, Tanimine N, Tahara H, Ide K, Kobayashi T, Tanaka Y, Tzakis AG, Nishida S, Ohdan H. Clinical Efficacy of Adjuvant Immunotherapy for Liver Transplant Recipients with Exceeding Japan Criteria of Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-efficacy-of-adjuvant-immunotherapy-for-liver-transplant-recipients-with-exceeding-japan-criteria-of-hepatocellular-carcinoma-using-donor-liver-derived-natural-killer-cells/. Accessed June 29, 2022.
« Back to 2022 American Transplant Congress